292 related articles for article (PubMed ID: 32998876)
1. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.
Bajaj JS; Sikaroodi M; Shamsaddini A; Henseler Z; Santiago-Rodriguez T; Acharya C; Fagan A; Hylemon PB; Fuchs M; Gavis E; Ward T; Knights D; Gillevet PM
Gut; 2021 Jun; 70(6):1162-1173. PubMed ID: 32998876
[TBL] [Abstract][Full Text] [Related]
2. Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.
Saboo K; Shamsaddini A; Iyer MV; Hu C; Fagan A; Gavis EA; White MB; Fuchs M; Heuman DM; Sikaroodi M; Iyer RK; Gillevet PM; Bajaj JS
J Hepatol; 2021 Jan; 74(1):80-88. PubMed ID: 32679299
[TBL] [Abstract][Full Text] [Related]
3. Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients With Cirrhosis.
Shamsaddini A; Gillevet PM; Acharya C; Fagan A; Gavis E; Sikaroodi M; McGeorge S; Khoruts A; Albhaisi S; Fuchs M; Sterling RK; Bajaj JS
Gastroenterology; 2021 Aug; 161(2):508-521.e7. PubMed ID: 33857456
[TBL] [Abstract][Full Text] [Related]
4. Linkage of gut microbiome with cognition in hepatic encephalopathy.
Bajaj JS; Ridlon JM; Hylemon PB; Thacker LR; Heuman DM; Smith S; Sikaroodi M; Gillevet PM
Am J Physiol Gastrointest Liver Physiol; 2012 Jan; 302(1):G168-75. PubMed ID: 21940902
[TBL] [Abstract][Full Text] [Related]
5. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.
Bajaj JS; O'Leary JG; Tandon P; Wong F; Kamath PS; Biggins SW; Garcia-Tsao G; Lai J; Fallon MB; Thuluvath PJ; Vargas HE; Maliakkal B; Subramanian RM; Thacker LR; Reddy KR
Aliment Pharmacol Ther; 2019 Jun; 49(12):1518-1527. PubMed ID: 31032966
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
Schulz C; Schütte K; Vilchez-Vargas R; Vasapolli R; Malfertheiner P
Dig Dis; 2019; 37(2):161-169. PubMed ID: 30428474
[TBL] [Abstract][Full Text] [Related]
7. Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
Patel VC; Lee S; McPhail MJW; Da Silva K; Guilly S; Zamalloa A; Witherden E; Støy S; Manakkat Vijay GK; Pons N; Galleron N; Huang X; Gencer S; Coen M; Tranah TH; Wendon JA; Bruce KD; Le Chatelier E; Ehrlich SD; Edwards LA; Shoaie S; Shawcross DL
J Hepatol; 2022 Feb; 76(2):332-342. PubMed ID: 34571050
[TBL] [Abstract][Full Text] [Related]
8. Altered profile of human gut microbiome is associated with cirrhosis and its complications.
Bajaj JS; Heuman DM; Hylemon PB; Sanyal AJ; White MB; Monteith P; Noble NA; Unser AB; Daita K; Fisher AR; Sikaroodi M; Gillevet PM
J Hepatol; 2014 May; 60(5):940-7. PubMed ID: 24374295
[TBL] [Abstract][Full Text] [Related]
9. Chronic Rifaximin Use in Cirrhotic Patients Is Associated with Decreased Rate of C. difficile Infection.
Feuerstadt P; Hong SJ; Brandt LJ
Dig Dis Sci; 2020 Feb; 65(2):632-638. PubMed ID: 31440997
[TBL] [Abstract][Full Text] [Related]
10. Low Predictability of Readmissions and Death Using Machine Learning in Cirrhosis.
Hu C; Anjur V; Saboo K; Reddy KR; O'Leary J; Tandon P; Wong F; Garcia-Tsao G; Kamath PS; Lai JC; Biggins SW; Fallon MB; Thuluvath P; Subramanian RM; Maliakkal B; Vargas H; Thacker LR; Iyer RK; Bajaj JS
Am J Gastroenterol; 2021 Feb; 116(2):336-346. PubMed ID: 33038139
[TBL] [Abstract][Full Text] [Related]
11. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
Flamm SL
Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
[TBL] [Abstract][Full Text] [Related]
12. Alterations in gut virome are associated with cognitive function and minimal hepatic encephalopathy cross-sectionally and longitudinally in cirrhosis.
Jinato T; Sikaroodi M; Fagan A; Sterling RK; Lee H; Puri P; Davis BC; Fuchs M; Gavis E; Gillevet PM; Bajaj JS
Gut Microbes; 2023 Dec; 15(2):2288168. PubMed ID: 38010871
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes of Oral Zinc Therapy in Hepatic Encephalopathy Treatment.
Fritz MK; Mangino AA; Hunt TV; Pitcock CT; Dugan AJ; Karri K; Yarra P
Ann Pharmacother; 2023 Aug; 57(8):899-906. PubMed ID: 36367093
[TBL] [Abstract][Full Text] [Related]
14. Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy.
Hayakawa Y; Tamaki N; Nakanishi H; Kurosaki M; Tanaka Y; Inada K; Ishido S; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Kaneko S; Yasui Y; Takahashi Y; Tsuchiya K; Okamoto R; Izumi N
Intern Med; 2023 Apr; 62(7):973-978. PubMed ID: 36070941
[TBL] [Abstract][Full Text] [Related]
15. Durability of rifaximin response in hepatic encephalopathy.
Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
[TBL] [Abstract][Full Text] [Related]
16. Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding.
Higuera-de-la-Tijera F; Servín-Caamaño AI; Salas-Gordillo F; Pérez-Hernández JL; Abdo-Francis JM; Camacho-Aguilera J; Alla SN; Jiménez-Ponce F
Can J Gastroenterol Hepatol; 2018; 2018():3015891. PubMed ID: 30079329
[TBL] [Abstract][Full Text] [Related]
17. The impact of rifaximin on the hospital burden and infections in patients with hepatic encephalopathy: a retrospective observational study.
De Graeve J; Vanderstraeten E; Delvaeye T; De Lepeleere S; De Somer T; Van Steenkiste C
Acta Gastroenterol Belg; 2022; 85(3):433-437. PubMed ID: 35833904
[TBL] [Abstract][Full Text] [Related]
18. Impact of bacterial infections and spontaneous bacterial peritonitis prophylaxis on phage-bacterial dynamics in cirrhosis.
Bajaj JS; Rodriguez MP; Fagan A; McGeorge S; Sterling RK; Lee H; Luketic V; Fuchs M; Davis BC; Sikaroodi M; Gillevet PM
Hepatology; 2022 Dec; 76(6):1723-1734. PubMed ID: 35561076
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
Irimia R; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study.
Lv XY; Ding HG; Zheng JF; Fan CL; Li L
World J Gastroenterol; 2020 Jan; 26(2):199-218. PubMed ID: 31988585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
